PECHER GABRIELE has a total of 16 patent applications. Its first patent ever was published in 1997. It filed its patents most often in WIPO (World Intellectual Property Organization), Germany and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are REGENESANCE B V, JIANGSU RUNJIE BIOTECHNOLOGY CO LTD and TSITOS BAJOTEKNOLODZHI AG.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 5 | |
#2 | Germany | 4 | |
#3 | EPO (European Patent Office) | 3 | |
#4 | Australia | 1 | |
#5 | Brazil | 1 | |
#6 | Canada | 1 | |
#7 | China | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Pecher Gabriele | 16 |
#2 | Schirrmann Thomas | 1 |
Publication | Filing date | Title |
---|---|---|
DE102015005097A1 | Chimeric antigen receptor (CAR) for cancer immunotherapy | |
DE102010044321A1 | New use of a YT cell line for the treatment of malignant diseases and viral infections as well as for the production of interferon gamma | |
DE10121113A1 | Genetically modified YT cell line and its use | |
DE10048710A1 | Composition for treating or preventing tumors, comprises plasmids, and optionally recombinant viruses, that express mucin and carcino-embryonal antigen | |
WO9740182A1 | Genetically transfected human dendritic cells, their production and use, preferably as vaccines |